Grufity logo
Grufity logo
ANTX

ANTX - AN2 Therapeutics, Inc. Stock Price, Fair Value and News

$4.89-0.11 (-2.20%)
Market Closed as of 22 Jul 2026, 04:00 pm ET

Price Targets

ANTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANTX Price Action

Last 7 days

4.7%

Last 30 days

-9.4%

Last 90 days

14.2%

Trailing 12 Months

340.5%

ANTX RSI Chart

ANTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANTX Valuation

Market Cap

176.1M

Price/Earnings (Trailing)

-5.1

Price/Sales (Trailing)

115.34

Price/Free Cashflow

-5.63

ANTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ANTX Fundamentals

ANTX Revenue

Revenue (TTM)

1.4M

ANTX Earnings

Earnings (TTM)

-34.5M

Earnings Growth (Yr)

5.83%

Earnings Growth (Qtr)

-15.37%

ANTX Profitability

Return on Equity

-42.24%

Return on Assets

-39.47%

Free Cashflow Yield

-17.78%

ANTX Investor Care

Shares Dilution (1Y)

19.84%

Diluted EPS (TTM)

-1.09

Revenue & Growth

How AN2 Therapeutics, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202294.0K307.0K748.0K1.4M
2021---69.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About AN2 Therapeutics, Inc.

ANTX
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
 CEO
 WEBSITEan2therapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES35

AN2 Therapeutics, Inc. Frequently Asked Questions

ANTX is the stock ticker symbol of AN2 Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jul 22 2026, market cap of AN2 Therapeutics, Inc. is 176.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Wed Jul 22 2026, ANTX's PE ratio (Price to Earnings) is -5.1 and Price to Sales (PS) ratio is 115.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANTX PE ratio will change depending on the future growth rate expectations of investors.